A Blood Test for the Detection of Breast Cancer: Syantra Receives CE Mark Approval for their Breast Cancer Test built on the Syantra DX Liquid Biopsy Platform

"Syantra's blood-based test may help improve breast cancer detection for women with high-risk of developing breast cancer, particularly young individuals with genetic predisposition and women with dense breasts or diverse ethnic backgrounds. For those women, standard screening mammogram may be inadequate and more sensitive tests are urgently needed," said Dr. Massimo Cristofanilli, Professor of Medicine, Director of Breast Medical Oncology and Associate Director of Precision Medicine in the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine.   Dr. Cristofanilli also serves as a paid scientific advisory board member for Syantra Inc.

"Syantra's blood-based test may help improve breast cancer detection for women with high-risk of developing breast cancer, particularly young individuals with genetic predisposition and women with dense breasts or diverse ethnic backgrounds. For those women, standard screening mammogram may be inadequate and more sensitive tests are urgently needed," said Dr. Massimo Cristofanilli, Professor of Medicine, Director of Breast Medical Oncology and Associate Director of Precision Medicine in the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine.   Dr. Cristofanilli also serves as a paid scientific advisory board member for Syantra Inc.

About Syantra 

Syantra is a precision biotechnology company changing the way cancer is detected and treated. Its flagship product, Syantra DX^TM Breast Cancer, is a minimally invasive and high-performance blood test for the detection of breast cancer, at the earliest stages.

Contact 

For more information about Syantra, and the Syantra DX^TM Breast Cancer test, please visit: www.syantra.com

Social Media: LinkedIn, Twitter, Facebook, Instagram

Photo - https://mma.prnewswire.com/media/2052918/Syantra_Inc__A_Blood_Test_for_the_Detection_of_Breast_Cancer__Sy.jpg 

View original content:https://www.prnewswire.co.uk/news-releases/a-blood-test-for-the-detection-of-breast-cancer-syantra-receives-ce-mark-approval-for-their-breast-cancer-test-built-on-the-syantra-dx-liquid-biopsy-platform-301796078.html